Bioatrix

Sydney, Australia Founded: 2012 • Age: 14 yrs Acquired By ZZ Biotech
Developing activated protein C (aPC)-based products primarily for wound healing
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Bioatrix

Bioatrix is a company based in Sydney (Australia) founded in 2012 was acquired by ZZ Biotech in January 2016. Bioatrix operates in a competitive market with competitors including QBiotics, MediWound, Ilya Pharma, Resolution Therapeutics and ProFibrix, among others.

  • Headquarter Sydney, Australia
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Medical Devices & Diagnostics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    ZZ Biotech

    (Jan 12, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Bioatrix

Premium access

Detailed funding history for Bioatrix

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Bioatrix

Bioatrix has secured backing from 1 investor. Prominent investors backing the company include ZZ Biotech.

All
Investor Description Founded Year Domain Location
Genetically engineered proteins for stroke and brain disorders are developed.
Locked Locked Locked
Premium access

Investor details for Bioatrix

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Bioatrix

Investments
Premium access

Investment portfolio details for Bioatrix

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Bioatrix

Premium access

Detailed financials for Bioatrix

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Bioatrix Comparisons

Bioatrix Primary company
Description
Developing activated protein C (aPC)-based products primaril...
Location
Sydney, Australia
Founded Year
2012
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Bioatrix

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Bioatrix

Bioatrix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as QBiotics, MediWound, Ilya Pharma, Resolution Therapeutics and ProFibrix, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Small molecules from plant extracts are developed for medical applications.
Locked Locked Locked
Enzymatic therapies for tissue repair and regeneration are developed.
Locked Locked Locked
Biological drugs for skin and mucosa wound treatment are developed.
Locked Locked Locked
Macrophage cell therapies are developed for inflammatory and liver diseases.
Locked Locked Locked
Powdered fibrin sealant for surgical bleeding
Locked Locked Locked
Topical formulations for corneal wounds, ulcers, and scars are developed.
Premium access

Detailed competitors of Bioatrix

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Bioatrix

Premium access

Complete news archive for Bioatrix

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bioatrix

Bioatrix was founded in 2012.

Bioatrix is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.

Bioatrix is a regenerative medicine company primarily focussed on developing protein-based products for wound healing. It has licensed the technology based on the Activated Protein C (aPC) from the Sydney University. These proteins claim to have shown potential as a treatment for inflammatory skin diseases, such as psoriasis and eczema, and hypertrophic scarring. The company is currently working on phase 2 trials wound healing. In December 2015, ZZ Biotech acquired Bioatrix and since then it is working as its subsidiary.

Bioatrix's top competitors include Ilya Pharma, QBiotics and Tempo Therapeutics.

Bioatrix has 1 investor. Key investors include ZZ Biotech.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available